Abstract: OBJECTIVE To review the economic evaluation of bevacizumab in treatment for patients with ovarian cancer. METHODS Search economic evaluation studies of bevacizumab for ovarian cancer on databases such as PubMed, Medline, Cochrane Library, CNKI, VIP Database and Wanfang Database. RESULTS Ten included studies demonstrate that incremental cost effectiveness ratio (ICER) of bevacizumab plus standard first-line chemotherapy versus chemotherapy alone exceeds the willingness-to-pay (WTP) threshold in most countries. Regarding platinum-resistant ovarian patients, adding bevacizumab to chemotherapy is cost-effective compared with chemotherapy alone. CONCLUSION Bevacizumab plus standard first-line chemotherapy is not cost-effective compared with chemotherapy alone in treatment of advanced ovarian. However, the combination of bevacizumab plus standard chemotherapy might be a cost-effective strategy given an enough reduction of drug price in ovarian patients at high risk of disease progression. As for second-line treatment, bevacizumab plus chemotherapy can be a cost-effective strategy.